Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29152238 | 1.00 | GAA (0.50) | GAAMAPTCTRB1BRD4TSHR | |
| SCHEMBL13923613 | 1.00 | GAA (0.50) | GAAMAPTCTRB1BRD4TSHR | |
| SCHEMBL17073790 | 0.89 | BRD4 (0.49) | GAAMAPTCTRB1BRD4MEN1 | |
| SCHEMBL13163227 | 0.84 | CTRB1 (0.39) | GAAMAPTCTRB1BRD4CYP19A1 | |
| SCHEMBL24593954 | 0.84 | CTRB1 (0.39) | GAAMAPTCTRB1BRD4 | |
| SCHEMBL5239565 | 0.80 | ALDH1A1 (0.46) | MAPTLMNAMAP1LC3BMEN1KMT2A | |
| SCHEMBL5233147 | 0.80 | MAP1LC3B (0.42) | CYP19A1MAP1LC3B | |
| SCHEMBL9336844 | 0.80 | SRD5A1 (0.46) | GAAMAPTCTRB1BRD4TSHR | |
| SCHEMBL909265 | 0.80 | CTRB1 (0.47) | GAAMAPTCTRB1BRD4TSHR | |
| SCHEMBL657291 | 0.78 | CTRB1 (0.68) | GAAMAPTCTRB1BRD4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181081-B | Synthesis method of beta-phenyl-gamma-butyrolactone | 青岛科技大学 | 2024-05-17 | — | — | CN | claimed |
| CN-115181081-A | Synthesis method of beta-phenyl-gamma-butyrolactone | 青岛科技大学 | 2022-10-14 | — | — | CN | claimed |
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | L'OREAL S.A. | 2007-06-14 | — | — | US | claimed |
| US-20040225135-A1 | Method of producing optically active lactone compound | KYUSHA UNIVERSITY (JP) | 2004-11-11 | — | — | US | claimed |
| US-6784302-B2 | HIGHER ENANTIOMERIC EXCESS BY USING A SPECIFIED ZIRCONIUM (SALEN) COMPLEX AS CATALYST TO CONDUCT A BAEYER-VILLIGER REACTION OF A CYCLIC KETONE; OXIDATION USING A HYDROGEN PEROXIDE OXIDIZER TO PRODUCE CYCLIC ESTERS | KYUSHU UNIVERSITY (JP) | 2004-08-31 | — | — | US | claimed |
| EP-1449840-A1 | Method of producing optically active lactone compound | Kyushu University (JP) | 2004-08-25 | — | — | EP | claimed |
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | claimed |
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2004-01-15 | — | — | US | claimed |
| EP-1352908-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2003-10-15 | — | — | EP | claimed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | claimed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | claimed |
| CN-118562626-B | Trichoderma citrinoviride strain capable of producing various furanones and screening culture method and application thereof | 江苏今世缘酒业股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-118562626-A | Trichoderma citrinoviride strain capable of producing various furanones and screening culture method and application thereof | 江苏今世缘酒业股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-115181081-B | Synthesis method of beta-phenyl-gamma-butyrolactone | 青岛科技大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-115181081-B | Synthesis method of beta-phenyl-gamma-butyrolactone | 青岛科技大学 | 2024-05-17 | — | — | CN | disclosed |
| WO-2000038638-A1 | DYEING METHOD USING A SPECIFIC ACTIVE METHYLENE COMPOUND AND A COMPOUND SELECTED AMONG A SPECIFIC ALDEHYDE, A SPECIFIC KETONE, A QUINONE AND A DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE DERIVATIVE | L'OREAL (FR) | 2000-07-06 | — | — | WO | disclosed |
| CN-1050830-C | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | SCHERING CORP (US) | 2000-03-29 | — | — | CN | disclosed |
| CN-1131416-A | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | SCHERING CORP (US) | 1996-09-18 | — | — | CN | disclosed |
| CN-1012495-B | Preparation method and application of benzoquinone derivative | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1991-05-01 | — | — | CN | disclosed |
| CN-85105976-A | The preparation method of quinone derivatives and purposes | — | 1986-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | CYC1, CYP11B1, CYP17A1 | GAA 381/4885MAPT 3253/4885CTRB1 1321/4885 |
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | KRT18, NDUFB5, NDUFB7 | GAA 4054/4885MAPT 685/4885CTRB1 3842/4885 |
| US-20040225135-A1 | Method of producing optically active lactone compound | PPOX, CYP11B1, CYP17A1 | GAA 721/4885MAPT 2958/4885CTRB1 3254/4885 |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | SOD1, OAT, SOD3 | GAA 618/4885MAPT 2241/4885CTRB1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.